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WHAT THIS PAPER ADDS
 This is a single-centre prospective randomised controlled trial comparing the cost and effectiveness of two popular endovenous
treatments for venous insufﬁciency: EVLA with concurrent phlebectomies and UGFS to the GSV. It is believed that EVLA is more
effective but more expensive. UGFS, on the other hand, is more likely to require additional treatments with foam but may be more
acceptable in terms of pain, analgesia requirements and return to normal activities.
 This study has quantiﬁed these differences using micro-costing evaluations alongside duplex, functional, clinical and haemody-
namic assessments leaving the clinician to decide which treatment is the most acceptable.a r t i c l e i n f o
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Objectives: Quantify endovenous laser ablation (EVLA) with concurrent phlebectomies and ultrasound-
guided foam sclerotherapy (UGFS) in cost and effectiveness at 3 weeks and 3 months.
Design: Single-centre, prospective, randomised controlled trial.
Patients: One hundred patients (100 legs), C2e6, age 21e78, M:F 42:58, with primary varicose veins
received either EVLA under local anaesthetic or UGFS.
Methods: Assessments included duplex, Aberdeen varicose vein questionnaire (AVVQ), venous clinical
severity score (VCSS), venous ﬁlling index (VFI), visual analogue 7-day pain score and analgesia
requirements. Additional treatments with UGFS were performed, if required. Micro-costing, using
individually timed treatments, was based on consumables, staff pay and overheads.
Results: Changes in AVVQ, VCSS and VFI values (3 months) did not demonstrate any signiﬁcant difference
between groups. At 3 months, the above-knee GSV occlusion rate (without co-existing reﬂux) was not
signiﬁcantly different between the groups (74% vs 69%; EVLA vs UGFS; P ¼ .596). Of the 9 haemodynamic
failures in each group, 7 EVLA patients and 4 UGFS patients had co-existing cross-sectional above-knee
GSV occlusion at some point. However, UGFS signiﬁcantly outperformed EVLA in cost, treatment dura-
tion, pain, analgesia requirements and recovery.
Conclusions: UGFS is 3.15 times less expensive than EVLA (£230.24 vs £724.72) with comparable effec-
tiveness but 56% (versus 6%) required additional foam (ISRCTN:03080206).
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.ation at: XXV Silver Jubilee
y. Athens, Greece. September
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ciety for Vascular Surgery. PublishIntroduction
Varicose veins affect approximately 25% of the western
population1 and are a sign of underlying chronic venous insufﬁ-
ciency. Their treatment is directed at improving venous haemo-
dynamics as well as obliterating symptomatic reﬂuxing varicose
tributaries.ed by Elsevier Ltd. All rights reserved.
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sclerotherapy (UGFS)3 are now established techniques at obliter-
ating failing saphenous trunks, the commonest haemodynamic
abnormality in superﬁcial venous insufﬁciency (SVI). Laser treat-
ment requires tumescent anaesthesia, a protected environment
and higher initial cost with the advantages of a single session of
treatment. Foam sclerotherapy, in contrast, is acknowledged to
have inferior results on the great saphenous vein (GSV),4 may
require more than one extra treatment but has lower cost and is
easily repeatable. The aims of the study were to quantify the
differences between both treatment options in terms of effective-
ness, cost, complications and return to normal activities (recovery).
Methods
This study was approved by the Regional Ethics Committee (No:
08/H0710/78) and is registered on a public database (www.
controlled-trials.com, No: ISRCTN:03080206). This was a prospec-
tive, single-centre, randomised controlled trial on 100 patients
with primary symptomatic varicose veins. Written consent was
then obtained from suitable participants whomet the inclusion and
exclusion criteria (Table 1). Randomisation was performed with
numbered sealed envelopes. Fifty patients/legs received local
anaesthetic EVLA with concurrent phlebectomies and 50 patients/
legs received UGFS to the incompetent GSV. In patients with
bilateral disease, the most severely affected leg was treated. The
ﬂow of patients through the study is shown in Fig. 1.
Investigation protocol
All patients underwent clinical, functional, haemodynamic and
duplex assessment at the beginning of the study. Clinical stage was
assessed using the C component of the CEAP classiﬁcation.5 The
venous clinical severity score (VCSS) was used to assess the clinical
severity before and after treatment.6
The Aberdeen varicose vein questionnaire (AVVQ) is a disease
speciﬁc quality of life (QoL) questionnaire which was used as
a patient reported outcome measure to assess the impact of
treatment.7 Patients were encouraged to ﬁll in the questionnaire
during their clinic visit and this ensured 100% completion. It was
completed after treatment was guaranteed, to prevent its use to
qualify for treatment. Haemodynamic measurements were quan-
tiﬁed with the venous ﬁlling index (VFI) in ml/sec using air pleth-
ysmography (APG apparatus, ACI Medical, San Marcos, CA 92078,
USA).8 The calf sensor cuff was calibrated with an inﬂation pressure
of 6 mmHg.
The superﬁcial and deep leg veins, above knee (AK) and below
knee (BK), were assessed for reﬂux, occlusion and competency,Table 1
Inclusion and exclusion criteria.
Inclusion criteria
Patients with primary symptomatic varicose veins
SFJ reﬂux (>0.5 s) on duplex
Suitability for both techniques: laser and foam
Exclusion criteria
Sapheno-popliteal junction incompetence
GSV diameter >12 mm
Previous surgery or sclerotherapy in the study leg
Previous or current deep vein thrombosis
Known coagulopathy
Arterial occlusive disease (ABPI < 0.8)
Active malignancy
Pregnancy
Known allergy to local anaesthetic or sclerosing agentsbefore and after each intervention. Colour duplex was performed
by the same experienced operator (MA) using a portable Sonosite
Titan duplex scanner (SonoSite Inc., Bothell, WA 98021-3904, USA)
ﬁtted with a linear 7 MHz transducer. Reﬂux was induced using
a manual calf compression and release manoeuvre. Reﬂux was
signiﬁcant if the duration was >0.5 s for superﬁcial veins and >1 s
for deep veins. Occlusion was deﬁned as an absence of ﬂow with
incompressibility of any length across the segment of vein under
investigation. Competency was deﬁned as compressibility
(patency) with an absence of ﬂow or the presence of ante-grade
ﬂow. The diameter of the reﬂuxing GSV, excluding dilatations,
was obtained by taking the average of three measurements: 2 cm
below the saphenofemoral junction (SFJ), at mid-thigh and 5 cm
above the popliteal skin crease.
Endovenous procedures
All EVLA procedures were performed in a day surgery theatre
with the ELVeS PainLess diode laser, delivering intermittent
energy using a 1470 nmwavelength bare-tipped ﬁbre (Biolitec, Inc.
East Longmeadow, MA, 01028, USA). The saphenous vein was
prepared using tumescent anaesthesia (40 ml of 0.5% Bupivacaine
in 1000 ml 0.9% saline) and patients were placed in the Trende-
lenburg position prior to ablation. The access site was near the
knee, not necessarily at the distal end point of reﬂux. The median
and inter-quartile range (IQR) of energy deliveredwas 69 (66e76) J/
cm along 31 (25e36) cm of the GSV. Incompetent saphenous
tributaries were treated concurrently using phlebectomy hooks.
Padding and crepe bandages were administered and a thigh length
anti-embolism stocking was advised for 3 weeks.
The UGFS procedure took place in an outpatient consultation
room and was primarily used to treat an incompetent GSV.
Signiﬁcant tributaries were treated if required, at a further session.
A maximum of 12 mls of foam was injected during a single session
in order to comply with the European recommendations.9 Foam
was prepared by agitating 1.2 ml of 1% sodium tetra-decyl sulphate
(STS, STD Pharmaceuticals, Hereford, HR4 0EL, UK) in 4.8 mls of air
to produce 6mls of foam. This was then injected into the saphenous
trunk at knee level, using an 18-gauge straight intravenous cannula,
with the patient supine and the leg elevated at 45. The median
(IQR) of foam injected was 12 (10e12) ml. The extent and direction
of foam within the target veins was visualised using ultrasound.
Tributaries were treated as required on a subsequent occasion
using a 21-gauge butterﬂy needle. A full length, 23e32 mmHg,
graduated elastic compression (GEC) stocking with a waist
attachment was applied for 3 weeks (Medi, D-95448 Bayreuth,
Germany). In patients with a GSV diameter 8 mm UGFS was
modiﬁed using tumescence.10 This took place in a day surgery
clinical room and involved the deployment of foam into the GSV
using a 14-gauge, 25 cm intravenous catheter.10 In all initial UGFS
sessions, foam injection occurred after the GEC stocking was
partially applied to the knee. This was in order to localise the foam
and prevent potential ante-grade displacement into deep veins
which may occur during the initial pull-up of the stocking. In
subsequent UGFS sessions, the sclerosant was usually directed at
calf veins and the above technique was not applicable.
Advice to patients
Patients were given written information regarding recovery
from EVLA and UGFS. Both groups were told they could resume
normal activity immediately and were encouraged to walk at
regular intervals. Patients were also asked to complete 7-day pain
charts with a 100mmvisual analogue scale (VAS), and to record the
days analgesia was taken.
Figure 1. Patient disposition.
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A micro-costing approach, from the ground-up, was used to
assess the cost of each treatment.11 Consumables, staff pay,procedure location, overheads and individually timed treatments
were included in the analysis. This approach provided direct
comparisons between treatments and avoided the wide scope of
overheads in the running costs of a hospital, like building’s capital,
Table 2
Demographic and baseline characteristics between the EVLA and UGFS groups.
Median values, range and percentages are presented.
EVLA Group UGFS Group P value
Mean age 47.4 (21e74) 48.5 (22e78) 0.733a
Female 31 (62%) 27 (54%) 0.418b
Bilateral disease 28 (56%) 32 (64%) 0.414b
C of CEAP class
2 22 (44%) 10 (20%)
3 7 (14%) 8 (16%)
4 15 (30%) 24 (48%)
5 & 6 6 (12%) 8 (16%)
0.074c
VCSS 6 (2e20) 7 (3e17) 0.114d
AVVQ 20 (1e53) 25 (4e50) 0.085d
VFI (ml/sec) 4.7 (0.9e17.8) 5.9 (1.1e15.5) 0.367d
GSV diameter (mm) 7 (4e12) 8 (5e12) 0.115d
BK GSV Reﬂux 29 (58%) 37 (74%) 0.091b
a t-test.
b Chi-square test.
c Chi-square of 6.93.
d Mann-Whitney U test.
Table 3
Breakdown of expenditure comparing EVLA against UGFS.
Category Comment EVLA T-UGFS UGFS
n ¼ 50 n ¼ 27 n ¼ 23
Staff Pay per minute (£)
Surgeon (SPR) 0.83 0.83 0.83
Duplex (MA) 0.56 0.56
Trainee 0.50
Nurse (b6) 0.40
Nurse (b5) 0.33 0.33
HCA (b2) 0.21
Subtotal A 2.27 1.72 1.39
Consumables (£)
Laser Kit 235.00
Thigh stocking 27.57 27.57
Micropuncture set 20.23
Central line 16.33
Foam (1% STS) 10.25 10.25
Basic Set 10.00
Tumescent tubing 6.00 6.00
Bupivacaine (0.5%) 4.35
Velband & Crepe 3.78
1000 ml 0.9% saline 3.34 3.34
Sterilisation 2.77
Needles 1.12 1.12
Subtotal B 286.59 64.61 37.82
Holding Area
£11.40/hour 45.60 22.80 11.40
Overheads
Theatre (£/min) 2.30
Percent (15%) 1.15 1.15
Summary
Fixed Cost (£) 332.19 87.41 49.22
Variable Cost (£/min) 4.57 1.72 1.39
Median treatment (min) 85 48 27
Index Totala p/p (£)b 720.64 195.47 99.76
Additional UGFS n ¼ 3 n ¼ 24 n ¼ 9
Additional cost (£68.05)c 204.15 1633.20 612.45
Grand Total p/p (£) 724.72 255.96 126.39
a Primary treatment costs.
b p/p ¼ per patient.
c Total for each group. This excludes the cost of a new stocking.
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Procedures were timed from the entry into the treatment area until
the departure as published previously.12
Follow-up
This was at 3 weeks following treatment and 3 months after the
last treatment session. The protocol allowed a maximum of two
additional treatment sessions with foam. The decision to offer
additional treatment was based on the patient’s informed choice
and independent of cost. Patients werewarned of a< 1% risk of DVT
and told that an un-occluded reﬂuxing AK GSV was a failure, irre-
spective of symptoms. Patients therefore could decide, with the
alternative of a 1 year review, if they needed additional treatment.
The follow-up evaluation included the VCSS, the AVVQ and the
VFI (at 3 months). The duplex assessment was aimed at detecting
a thigh or calf DVTand documenting reﬂux, competency and degree
of closurewithin the GSV, both AK and BK. The ultrasound endpoint
was the absence of GSV reﬂux at every point, not occlusion. A
partially patent but competent vein was not a treatment failure.
Patients were asked to return the 7-day post-procedural (VAS) pain
score (out of 100 for each day), state their analgesia requirements
and record the number of days to recover and resume normal
activities.
Statistical analysis
This study was powered on a meta-analysis which showed a 5
year recurrence rate (GSV recanalisation) with foam of 26.5% and
with laser 4.6%.4 For a type I error of 0.05 and a type II error of 0.20
the minimum sample size was 86. The number of patients was
increased to 100 to take into account loss to follow-up or protocol
violation. The 3 month results of this study are reported.
Statistical differences were evaluated between groups at base-
line using the independent samples t-test, chi square test, and the
ManneWhitney U test, as appropriate. Comparisons were made
within the same group (i.e. score changes over time) as well as
calculating improvement differences between groups (i.e. baseline
scores minus post-treatment scores). The ManneWhitney U-test
and Wilcoxon signed rank test were used as the basis of the anal-
ysis. All statistical tests were two-tailed. A linear statistical model
was assumed in each scoring system. Patients with missing data
were removed from the analysis at the point where the data were
absent. Data were analysed using SPSS Statistics 17 (SPSS Inc.,




Patients were compared across all assessment parameters as
depicted in Table 2. However, there was a trend for the UGFS
patients to have more severe baseline characteristics, but this
discrepancy was not sufﬁcient to reject the null hypothesis. The
median baseline VCSS, AVVQ, VFI and GSV diameters were high in
comparison to similar studies, conﬁrming severe disease.
Treatment duration and cost
The median (IQR) treatment duration of EVLA and UGFS was 85
(75e96) min and 35 (25e50) min respectively, P < .0005,
ManneWhitney U test. The median (IQR) treatment cost in the
EVLA group overall compared with the UGFS group was £724.72
(676.74e773.85) and £230.24 (123.20e259.91) respectively,P < .0005, ManneWhitney U test. The primary treatment costs and
the total cost, including the additional treatments with UGFS, are
shown in Table 3, with the breakdown of expenditure.
The signiﬁcantly increased costs in the EVLA group did not
demonstrate any overlap with UGFS. These costs were related to
the cost of the laser kit, increase in procedure duration, the running
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staff and other consumables. The cost of the thigh-length GCS was
the main consumable expenditure in UGFS.Figure 3. Boxplots compating time-taken to recovery and return to normal activity
with mean 7-day post-procedural pain scores. P < .0005 (ManneWhitney U test).Follow-up
The median (IQR) pain score during the 7 days following
treatment in the EVLA group was more than twice compared to the
UGFS group at 33/100 (18e54) and 14/100 (6e34) respectively,
P ¼ .005, ManneWhitney U test. The daily VAS pain score within
each group is depicted in Fig. 2. A similar factor increase was also
observed when the median (IQR) time taken to return to normal
activities and recover was compared: 7.5 (2e15) days for EVLA and
3 (1e10) days for UGFS, P ¼ .011, ManneWhitney U test. The EVLA
group required analgesia tablets for a median of 2 days (0e21) in
comparison to 0 days (0e14) with the UGFS group. Furthermore,
post-procedural pain scores were signiﬁcantly greater in all
patients who took over 10 days to recover (P < .0005,
ManneWhitney U test), as shown in Fig. 3.
The results of endovenous treatment on duplex outcomes
between both groups are demonstrated in Table 4. The GSV has
been divided into AK and BK parts because the intended effect of
the initial treatment was on AK outcomes. The BK GSV effects
however, were also recorded because subsequent UGFS, if required,
was mainly directed at the treatment of BK GSV reﬂux or tributary
disease. At 3 months, AK GSV occlusion, without reﬂux, was ach-
ieved in 74% of EVLA patients and 69% of UGFS patients. This
compares to an initial success rate at 3 weeks of 92% and 80%
respectively. Below knee GSV reﬂux was present in 46% and 42% of
patients at 3 months, respectively.
Treatment was successful (absence of AK GSV reﬂux) in 80% of
the patients in each group at 3 months. The patterns of closure and
reﬂux in those patients with above knee reﬂux at 3 months (9 in
each group) are explained in Table 5. In the EVLA group 7/9
reﬂuxing patients had occlusion (absence of ﬂow with incom-
pressibility of any length) compared to 4/9 reﬂuxing UGFS patients.
Three EVLA patients (6%) had subsequent UGFS for AK GSV
reﬂux, BKGSV reﬂux and anterior accessory saphenous vein (AASV)
reﬂux, respectively. The duplex ﬁndings on the 28 UGFS patients
(56%) who received additional sclerotherapy were 8 (16%) AK GSV
reﬂux, 12 (24%) BK GSV reﬂux, 7 (14%) tributary disease and 1 (2%)
AASV reﬂux.Figure 2. Daily pain scores comparing EVLA and UGFS using a Visual Analogue Scale
(VAS).The median (IQR) AVVQ, VCSS and VFI at 3 months was 5.8
(2.5e12.2), 1(0e3) and 1.5 (1.1e2.4) for EVLA and 12.4 (6e21.9), 2
(1e4) and 1.9 (1.3e2.7) for UGFS, respectively. Whilst this may
indicate a trend favouring EVLA, it should be noted that the baseline
scores were also better in the EVLA patients as seen in Table 2. The
improvements in the AVVQ, VCSS and VFI at 3 weeks and 3 months
are demonstrated in Table 6. There were no signiﬁcant differences
between both groups in terms of improvement although
improvements within both groups were all signiﬁcant (P < .0005,
Wilcoxon) at 3 months.
Side-effects and complications
There were no serious complications (Table 7). Five patients re-
attended before 3 weeks due to pain. Thrombotic complications
were recorded if there was severe pain or deep vein involvement.
Four patients in the UGFS group had side-effects following foam
injection (headache n¼ 1, cough n ¼ 1, dizziness n ¼ 2) all of which
disappeared within 30 min.
Discussion
This is a randomised controlled trial which compares the direct
procedural costs and early (3 month) effectiveness of EVLA versusTable 4
Ultrasound outcomes on the above and below knee GSV at 3 weeks (3w) and 3
months (3m). 1 ¼ Success deﬁned as occlusion (any length) without reﬂux;
2 ¼ Patent and competent (no occlusion); 3 ¼ Reﬂux anywhere along the GSV
segment (with or without occlusion); 4¼ Overall success, deﬁned as occlusion (with
or without reﬂux) or competency (patent and compressible with absence of ﬂow or
presence of ante-grade ﬂow). 5 ¼ Overall success, deﬁned as occlusion (with or
without reﬂux).
EVLA UGFS
3w (n ¼ 50) 3m (n ¼ 46) 3w (n ¼ 50) 3m (n ¼ 45)
Above Knee
1 46 (92%) 34 (73.9%) 40 (80%) 31 (68.9%)
2 3 (6%) 3 (6.5%) 2 (4%) 5 (11.1%)
3 1 (2%) 9 (19.6%) 8 (16%) 9 (20%)
4 49 (98%) 44 (95.7%) 44 (88%) 40 (88.9%)
5 46 (92%) 41 (89.1%) 42 (84%) 35 (77.8%)
Below Knee
1 17 (34%) 7 (15.2%) 10 (20%) 20 (44.4%)
2 26 (52%) 18 (39.1%) 16 (32%) 6 (13.3%)
3 7 (14%) 21 (45.7%) 24 (48%) 19 (42.2%)
Table 5
Patterns of above knee (AK) GSV closure in patients with residual AKGSV reﬂux, at 3
months.
Occluded Partial closure Patent Pattern of AK reﬂux
EVLA (n ¼ 9) 7/9 1/9 1/9 7/7 (distal)
UGFS (n ¼ 9) 4/9 3/9 2/9 3/4 (proximal)
1/4 (distal)
Table 7
Number of patients with side-effects or complications.
Patient Event EVLA Group UGFS Group
DVT (30% aDVT into Common Femoral Vein) 1
GSV thrombosis (both re-attended) 1 1
GSV saccular thrombosis (1 re-attended) 3
Tributary thrombosis 1 4
Groin haematoma (1 treated by family doctor) 2
Dermal thermal injury (1 re-attended) 2
Phlebectomy granuloma 1
Severe procedural pain (1 required a GA) 3
Headache/cough/dizziness (procedural) 4
Shingles (viral reactivation) 1
Vasovagal episode (procedure re-scheduled) 1
Severe stocking discomfort (re-attended) 1
a Deep vein thrombosis which disappeared within 8 weeks on oral Warfarin.
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outcome measures in our NHS treatment environment. The results
indicate that UGFS is less expensive on the background of compa-
rable effectiveness in terms of abolition of AK GSV reﬂux, disease
speciﬁc QoL, clinical severity and VFI improvements. There was also
signiﬁcantly shorter treatment duration, reduced post-operative
pain, reduced analgesia requirements and an earlier recovery
time in the UGFS group. However, 6% of EVLA patients and 56% of
UGFS patients required additional sclerotherapy to complete their
treatment which resulted in higher adjuvant costs for the UGFS
group.
The median costs for EVLA were considerably more expensive
than UGFS (£724.72 vs £230.24). These costs were calculated from
the ground up (micro-costing) and did not include overheads from
the capital and running costs of a public hospital. Outpatient
follow-up appointments, re-attendances, opportunity costs,
primary care costs and socioeconomic costs were all excluded from
this analysis. Furthermore, patients in high socioeconomic classes
are likely to have been treated in the private healthcare system,
where loss of earnings from days off work would have a greater
socioeconomic impact. Prices could not be compared because the
Department of Health price tariff for an elective day-case primary
unilateral varicose vein procedure without complications (irre-
spective of type of treatment) is currently set at £1,098 (HRG code
QZ10B).13
Costing from the ground up allows for a sensitivity analysis,
a process where the impact of expensive elements of a cost calcu-
lation can be assessed by their removal from the analysis. The cost
of EVLA could be reduced if the procedure is performed in a clinical
room in day surgery with reduced staff comprising of one surgeon,
a nurse and a health care assistant (HCA). The actual costs however,
have been provided (Table 3) using micro-costing in our setting. In
contrast to a recent randomised clinical trial,14 price (reimburse-
ment) was not added to cost. Also procedure times, not surgeons
times, were used in our calculations.
Further reductions, at least in terms of disposables, could also be
made if EVLA is performed bilaterally.15 The main reasons for the
high EVLA costs in our setting, was because the procedure was of
low volume and performed in main theatres. It was a multi-
specialty setting with multi-disciplinary nurses and a training
environment for the assistant surgeon. Furthermore, concurrent
stab phlebectomies increased the initial procedure time. The cost
for EVLA is likely to be less with another set-up.
The deﬁnition of duplex success in this study was very strict as
concurrent AK GSV reﬂux, even in the presence of occluded areas,Table 6
Functional, clinical and haemodynamic changes (improvements) at 3 weeks (3w)
and 3 months (3m) between EVLA and UGFS. Values represent change scores
(baseline minus post-treatment) using median (IQR).
EVLA UGFS Pa
AVVQ 3m 12 (11) 9 (11) 0.062
VCSS 3w 3 (2) 3 (5) 0.721
VCSS 3m 5 (2) 4 (3) 0.817
VFI (ml/sec) 3m 2.6 (3.3) 3.1 (4.9) 0.791
a Mann-Whitney U Test.was considered inadequate treatment. Reﬂux (>0.5 s) indicates
that there may be a signiﬁcant remaining varicose reservoir. This
can occur at the SFJ with reﬂux into an AASV or thigh tributary from
the GSV stump, or at the distal end with reﬂux into calf tributaries
from an incompetent GSV below an occlusion.16 The abolition of
GSV reﬂux from the onset may reduce recurrence, a hypothesis
which will be tested at the long term follow-up.
Below-knee EVLA has been shown to be safe and effective and if
this was performed in all of the study patients it would have
improved the duplex outcomes.16 Advances in duplex assessment
criteria are justiﬁed because they may be able to highlight deﬁ-
ciencies of technique and areas of inadequate treatment, at least in
haemodynamic terms.
This study was powered, based on a meta-analysis comparing
EVLA to UGFS.4 Success in these studies was deﬁned in terms of
occlusion, irrespective of length of obliterated GSV or co-existing
areas of reﬂux. As shown in Table 5, 9 patients in each group had
reﬂux within the AK GSV at 3 months and of these, 7 EVLA and 4
UGFS patients demonstrated occlusion across the entire cross-
sectional area of the GSV. These occlusion results are marginally
less than those reported in the meta-analysis cited ﬁgures at 3
months (EVLA: 89.1% vs 92.2%; UGFS: 77.8% vs 82.1%). A possible
explanation for this may be that our deﬁnition of competency as an
outcome was very strict and may have included patients which
other groups would have considered as occlusion. It remains to be
seen whether the results will be maintained after a longer follow-
up. The expectation is that the occlusion and reﬂux rates will be
equivalent because of the open access policy of further scle-
rotherapy to both groups, as and when required.17
The AVVQ, demonstrated a greater improvement in the EVLA
group at 3 months compared to UGFS but this was not signiﬁcant
(P¼ .062),Table 6. At3months theAVVQchangeswithinbothgroups
were signiﬁcant (P < .0005) and both exceeded the minimally
important difference value of 2.4, making them clinically relevant.18
It is apparent from other randomised controlled trials which
report pain after EVLA that this occurs up to the 10th post-operative
day.14,19 This is in agreement with the current study where daily
pain scores over 7 days have been charted (Fig. 2). The time taken to
return to normal activities however is much longer in the current
study compared with others,14,19 with a median of 7.5 days for EVLA
and 3 days for UGFS. Patients were speciﬁcally asked the time taken
for them to return to normal activities and recover. It may be that
patients in pain do not feel that they have recovered from the
procedure whereas they may be able to perform routine activities.
A relationship between post-procedural pain and time to recovery
was identiﬁed in this study, as illustrated in Fig. 3. Radial laser ﬁbres
and radiofrequency techniques have recently been acknowledged
to produce less post-procedural pain which may therefore result in
shorter recovery times.14
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UGFS. Foam is known to have inferior results in large calibre veins20
and is also associated with a higher rate of proximal thrombus
extension into the femoral vein.21 Tumescence was used to reduce
GSV calibre in UGFS patients with GSVs >8 mm diameter, with
catheter direction to facilitate foam delivery into its site of action.10
This was intended to improve standardisation of GSV preparation
between EVLA and UGFS.
Socioeconomic costs were excluded from the study, so every
time the treatment needs to be repeated, although inexpensive, the
loss of work is an important cost for society. This fact, together with
previous observations of a greater recurrence rate in the UGFS
group,4,14 may make the cost of UGFS to society higher in the long
term.Conclusion
Improvements in duplex, functional, clinical and haemody-
namic values did not demonstrate any signiﬁcant difference
between the two treatments at 3 months. There were
signiﬁcant differences in favour of UGFS in cost, treatment
duration, post-procedural pain scores, analgesia requirements
and time to recovery. Although the initial cost-saving with UGFS
cannot be ignored in public health care systems, these results
are too early to take into account the treatment costs of later
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